{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-112016","form_type":"8-K","ticker":"NEUP","cik":"0001191070","company_name":"Neuphoria Therapeutics Inc.","filed_at":"2024-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.869097+00:00","generated_at":"2026-05-28T23:31:49.977836+00:00","sec_items":["1.01","3.01","3.02","3.03","5.03","8.01","5.01","5.02","5.05","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neuphoria completes redomiciliation from Australia to Delaware; shares to trade under NEUP","bullets":["Effective Dec 23, 2024, Bionomics Ltd. became a wholly-owned subsidiary of Neuphoria; NEUP shares to trade on Nasdaq from Dec 24.","Exchange ratio: 1 Neuphoria share per 2,160 Bionomics shares or per 12 ADSs; options and warrants converted proportionally.","Board classified into three classes with staggered terms; Spyros Papapetropoulos CEO, Tim Cunningham CFO, Alan Fisher Chair.","Neuphoria adopted 2024 Equity Incentive Plan and new anti-takeover charter provisions (classified board, 66 2/3% supermajority, no written consent)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-112016","json":"https://secwatch.observer/filing/0001213900-24-112016.json","markdown":"https://secwatch.observer/filing/0001213900-24-112016.md","text":"https://secwatch.observer/filing/0001213900-24-112016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1191070/000121390024112016/0001213900-24-112016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1191070/000121390024112016/ea0225663-8k_neupho.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T23:31:49.977836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"177adc196fdca1a965676b9ff0a5bb0aaa6ef0c8","claim":"Neuphoria Therapeutics Inc.: Bylaws adopted in connection with redomiciliation.","evidence_excerpt":"rights of our shareholders are no longer governed by Bionomics’ organizational documents and instead are now governed by Neuphoria’s Amended and Restated Certificate of Incorporation and its bylaws","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390024112016/0001213900-24-112016-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"50f23270c022e1eb62679dd9df7ce412ff632daa","claim":"Neuphoria Therapeutics Inc.: Amended and Restated Certificate of Incorporation adopted in connection with redomiciliation.","evidence_excerpt":"rights of our shareholders are no longer governed by Bionomics’ organizational documents and instead are now governed by Neuphoria’s Amended and Restated Certificate of Incorporation","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390024112016/0001213900-24-112016-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"da1da50faff809b9708bfea9a3b0fdd32b851001","claim":"Neuphoria Therapeutics Inc.: Code of Conduct adopted, applies to all directors, officers and employees.","evidence_excerpt":"Neuphoria has adopted a Code of Conduct (the “Code”), which applies to all directors, officers and employees","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390024112016/0001213900-24-112016-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"code of ethics"}],"fact_type":"governance_change"},{"claim_id":"08f5192d677edf536b4799768154032636c1b91a","claim":"Neuphoria Therapeutics Inc. underwent a change of control involving Neuphoria Therapeutics Inc. (closed 2024-12-23).","evidence_excerpt":"On December 23, 2024 US time (“Effective Date”), the redomiciliation (“Redomiciliation”) of Bionomics Limited, an Australian corporation (“Bionomics”), was implemented under Australian law in accordance with a Scheme Implementation Agreement (as amended) between Bionomics and Neuphoria Therapeutics Inc., a Delaware corporation (“Neuphoria”).","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390024112016/0001213900-24-112016-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Neuphoria Therapeutics Inc."},{"label":"Closing","value":"2024-12-23"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}